NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics' JV Sapu Nano Deciparticle Platform Data Presentation
TL;DR
Oncotelic's Deciparticle platform offers a competitive edge by enabling rapid development of diverse cancer drugs with cGMP-ready manufacturing for faster clinical translation.
The Deciparticle platform formulates hydrophobic therapeutics into sub-20 nm nanoparticles using ISO-5 manufacturing, creating a versatile delivery system for multiple drug candidates.
This technology advances cancer treatment by improving drug delivery for high-unmet-need cancers and rare pediatric diseases, potentially saving lives and reducing suffering.
Oncotelic's nanomedicine platform can package diverse compounds like macrolides and peptides into tiny nanoparticles, showcasing innovative drug delivery science for oncology and immunology.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics' 45%-owned joint venture Sapu Nano presented new data at the 2025 San Antonio Breast Cancer Symposium showing its Deciparticle nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics into sub-20 nm nanoparticles suitable for IV delivery.
The platform can formulate macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams, and polyketides - all of which are hydrophobic therapeutics that are difficult to deliver effectively.
The findings confirm Deciparticle as a versatile, cGMP-ready delivery platform backed by ISO-5 manufacturing capabilities that support rapid translation to Phase 1 supply, positioning it as a modular engine for multiple oncology, immunology and peptide drug candidates.
Sapu Nano, Oncotelic Therapeutics' 45%-owned joint venture, presented the data at the 2025 San Antonio Breast Cancer Symposium.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.
Sapu003 represents the first drug candidate in a broader pipeline that will utilize the Deciparticle platform as a modular engine for multiple oncology, immunology and peptide drug candidates.
The platform is backed by ISO-5 manufacturing capabilities, which are cleanroom standards that support cGMP (current Good Manufacturing Practice) requirements for pharmaceutical production.
The latest news and updates relating to OTLC are available in the company's newsroom at https://nnw.fm/OTLC.
NetworkNewsWire is a specialized communications platform that distributes financial news and content for private and public companies and the investment community, and is part of the Dynamic Brand Portfolio at IBN.
In addition to the 45% ownership in Sapu Nano, Oncotelic also owns 45% of GMP Bio, another joint venture under CEO Dr. Vuong Trieu's leadership that is advancing its own pipeline of drug candidates complementing Oncotelic's strategic position.
Curated from InvestorBrandNetwork (IBN)
